Stock Analysis of Bellicum Pharmaceuticals Inc (BLCM) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BLCM
Close 0.201
Change -0.0201 / 9.09 %
Volume 17826.00
Vol Change 10878.00 / 156.56 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Bellicum Pharmaceuticals Inc
PE (TTM)

-369.13

Very Poor
Price / Book

567.07

Very Poor
Price / Sales

3076.59

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

1954.07 K

Enterprise Value

1954.07 K

ROA (TTM)

-47.83

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-833.48

Very Poor
Revenue

100433 %

1508.00 K
Net Profit

89508.78 %

-22378.00 K
Debt to Equity

0

Excellent
Altman Z Score

Indecisive
Quick Ratio

0

Poor
Cash Ratio

0

Poor


Highs/Lows of Bellicum Pharmaceuticals Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.2307 12.83 % 1.54 % 0.280.19213-Oct-2319-Oct-23
Two Week0.2957 31.99 % 3.42 % 0.30.19206-Oct-2319-Oct-23
One Month0.39 48.44 % 5.60 % 0.480.12525-Sep-2303-Oct-23
Three Month0.38 47.08 % 5.95 % 0.590.12523-Aug-2303-Oct-23
Six Months0.418 51.89 % 17.48 % 1.310.12508-May-2303-Oct-23
One year0.944 78.70 % 27.52 % 1.50.12524-Jan-2303-Oct-23
Two year2.26 91.10 % 29.70 % 2.20.12501-Apr-2203-Oct-23
Five year51.8 99.61 % 85.46 % 1.530.12518-Aug-2203-Oct-23


Technical View of Bellicum Pharmaceuticals Inc
RSI

34.97

Neutral
MACD

-0.0419

Bearish
ADX

12.84

Mild Bearish
Super Trend

0.412

Strong Bearish
Williams %R

-63.13

Neutral
CCI

-93.94

Neutral


EMA 5

0.225

Strong Bearish
EMA 15

0.264

Strong Bearish
EMA 50

0.338

Strong Bearish
EMA 100

0.407

Strong Bearish
SMA 100

0.381

Strong Bearish
SMA 200

0.576

Strong Bearish
SMA 5 / 20

0.230 / 0.296

Strong Bearish
SMA 15 / 50

0.266 / 0.361

Strong Bearish
SMA 50 / 200

0.361 / 0.576

Mild Bearish




Charts of Bellicum Pharmaceuticals Inc


Returns of Bellicum Pharmaceuticals Inc with Peers
Period / StockBLCMVRAXATHXMTP
1 Week-12.83%4.94%32.50%-5.89%
1 Mth-48.44%22.04%-90.29%-81.95%
3 Mth-47.08%2.39%-95.44%-89.62%
6mth-51.89%-68.27%-96.21%-96.39%
1 Year-78.70%-77.07%-98.55%-98.56%
2 Year-91.10%--99.89%-99.33%
5 Years-99.61%--99.93%-99.97%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Bellicum Pharmaceuticals Inc with Peers
Ratio / StockBLCMVRAXATHXMTP
PE-369.13-0.261-0.01490.847
P/B567.070.585-0.02361.16
ROA-47.83-169.55-193.28100.51
ROE0-213.230137.12
Debt To Equity00.016000.051
Revenue1508.00 K
100433 % 		8561.00
% 		80000.00
98.50 % 		699000
20.93 %
Net Income-22378.00 K
89508.78 % 		-5457.49 K
219.37 % 		-37507.00 K
44.89 % 		-7656.00 K
40.22 %


Technicals of Bellicum Pharmaceuticals Inc with Peers
Technical / StockBLCMVRAXATHXMTP-
ADX12.8418.2636.4250.25
CMF0.365-0.0244-0.506-0.294
MFI16.3872.2570.7812.27
RSI34.9761.3425.4120.22
MACD Abv SignalFalseTrueFalseTrue
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Bellicum Pharmaceuticals Inc

Address : 3730 Kirby Drive, Houston, TX, United States, 77098
Tel : 281 454 3424
URL : https://www.bellicum.com
Code : BLCM, ISIN : US0794814048, Exchange : PINK, Country : USA
Fiscal Year End : December
IPO date : 18_Dec_2014
Employee Count : 13

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.


Note : All Data Generated at the End of Trading Hours (EOD Data)